Market cap
$3,510 Mln
Recently Viewed
Clear All$28.94
$0.20
(0.70%)
As on 04-May-2026 16:22EDT
Market cap
$3,510 Mln
Revenue (TTM)
$589 Mln
P/E Ratio
17.1
P/B Ratio
3.6
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$0 Mln
ROE
0.3 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
9.2
Debt to Equity
0
Book Value
$7.5
EPS
$1.7
Face value
--
Shares outstanding
122,123,884
CFO
$311.30 Mln
EBITDA
$241.97 Mln
Net Profit
$194.60 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Catalyst Pharmaceuticals (CPRX)
| 24.0 | 17.2 | 14.8 | 16.5 | 20.4 | 42.8 | 46.4 |
|
BSE Sensex
| -8.7 | 5.4 | -7.7 | -4.0 | 8.1 | 9.7 | 11.8 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Catalyst Pharmaceuticals (CPRX)
| 11.8 | 23.9 | -9.6 | 174.7 | 102.7 | -10.9 | 95.3 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Catalyst Pharmaceuticals (CPRX)
|
28.9 | 3,509.8 | 589.0 | 214.3 | 46.8 | 25.5 | 17.1 | 3.6 |
| 13.1 | 4,092.8 | 2,323.3 | 137.9 | 12.3 | -- | 58.3 | 105.4 | |
| 41.0 | 5,243.8 | 1,003.8 | 22.4 | 6.8 | 7.5 | 227.6 | 14.2 | |
| 223.7 | 10,623.9 | 638.5 | -183.2 | -27.4 | -252.1 | -- | 120.3 | |
| 69.0 | 13,291.2 | 502.1 | -729.3 | -125.8 | 41.2 | -- | 123.7 | |
| 51.6 | 5,520.3 | 769.1 | 47.9 | 5.4 | 7.5 | 146.9 | 8.7 | |
| 13.3 | 11,388.0 | 345,831.0 | 56,586.0 | 21.5 | 15.8 | 18.9 | 2.9 | |
| 22.5 | 11,171.1 | 4,715.0 | -232.0 | 0.9 | -3.7 | -- | 1.7 | |
| 8.2 | 5,601.1 | 7,682.7 | 438.7 | 15.9 | 7.5 | 11.9 | 0.9 | |
| 56.2 | 3,703.2 | 391.6 | -76.6 | -19.3 | -16.4 | -- | 8.1 |
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. It offers Firdapse for the treatment of patients with... lambert-eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptor that is used to treat focal onset seizures, as well as tonic-clonic seizure; and AGAMREE, a corticosteroid for the treatment of duchenne muscular dystrophy. The company has license agreements with BioMarin Pharmaceutical Inc.; and a collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida. Read more
Co-Founder & Chairman
Mr. Patrick J. McEnany
Co-Founder & Chairman
Mr. Patrick J. McEnany
Headquarters
Coral Gables, FL
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Catalyst Pharmaceuticals Inc (CPRX) is $28.94 (NASDAQ) as of 04-May-2026 16:22 EDT. Catalyst Pharmaceuticals Inc (CPRX) has given a return of 20.35% in the last 3 years.
The P/E ratio of Catalyst Pharmaceuticals Inc (CPRX) is 17.11 times as on 01-May-2026.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
13.86
|
3.11
|
|
2024
|
16.08
|
3.62
|
|
2023
|
26.78
|
4.93
|
|
2022
|
25.42
|
7.03
|
|
2021
|
18.68
|
3.57
|
The 52-week high and low of Catalyst Pharmaceuticals Inc (CPRX) are Rs 32.56 and Rs 19.05 as of 05-May-2026.
Catalyst Pharmaceuticals Inc (CPRX) has a market capitalisation of $ 3,510 Mln as on 01-May-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Catalyst Pharmaceuticals Inc (CPRX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.